UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000052997
Receipt number R000060455
Scientific Title Effects of consumption of the test food on bowel movement in healthy Japanese: a randomized, placebo-controlled, double-blind, crossover comparison study
Date of disclosure of the study information 2023/12/04
Last modified on 2024/12/12 10:42:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of consumption of the test food on bowel movement in healthy Japanese

Acronym

Effects of consumption of the test food on bowel movement in healthy Japanese

Scientific Title

Effects of consumption of the test food on bowel movement in healthy Japanese: a randomized, placebo-controlled, double-blind, crossover comparison study

Scientific Title:Acronym

Effects of consumption of the test food on bowel movement in healthy Japanese

Region

Japan


Condition

Condition

Healthy Japanese

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to verify the effects of consuming the test food for two weeks on defecation status, subjectivity during bowel movements, and health-related quality of life in healthy Japanese men or women aged 20 or more and less than 65.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1. Defecation frequency and number of days with defecation

Key secondary outcomes

1. Amount of defecation, original questionnaire about bowel movement measured by visual analogue scale (VAS), health-related quality of life, stool shape, stool color, stool smell, and exhilarating feeling of defecation


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation


Institution consideration


Blocking

YES

Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Consumption of the test food for two weeks
Washout (Two weeks)
Consumption of the placebo food for two weeks

Interventions/Control_2

Consumption of the placebo food for two weeks
Washout (Two weeks)
Consumption of the test food for two weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1. Japanese
2. Men or women
3. Adults
4. Healthy individuals
5. Individuals aged 20 or more and less than 65 at the time of agreement to participate in this study
6. Individuals who defecate three to five times per week at screening period
7. Individuals who eat three meals per day with a mealtime variation of less than two hours throughout the week.
8. Individuals whose BMI is less than 30 kg/m2

Key exclusion criteria

Individuals (who)
1. under treatment for malignancy, heart failure, and myocardial infarct/with a medical history of them
2. have a pacemaker/an implantable cardioverter defibrillator
3. under treatment for chronic diseases
4. take "Foods for Specified Health Uses"/"Foods with Functional Claims"/medications/herbal medicines/supplements (may affect the study) and cannot avoid taking during the study
5. are at risk of developing an allergy to the test food's ingredients
6. are pregnant/lactating/planning to become pregnant during the study
7. have diseases that may substantially affect bowel movement
8. enrolled in other studies within 28 days before agreeing to participate/plan to participate another study during the study
9. are judged as ineligible to participate by the physician
10. are smokers/quit smoking within a year before agreeing to participate
11. drink >=60-g/day of alcohol
12. are planning to relocate (for work/education)/events with unusual stress/living with family members who plan them
13. live with infants or care recipients
14. sleep with children aged 1~6 years or with care recipients
15. plan an unusual overnight stay during the study
16. are restricted to go to the restroom
17. have extremely irregular lifestyle habits
18. are judged as ineligible to participate from clinical measurements at screening
19. exercise for >=30 min at least twice a week to maintain/improve physical strength
20. have weight variated 5 kg or over within 2 months
21. eat extremely unbalanced diet
22. have irregular lifestyle due to night work/shift work/others
23. plan to change their lifestyle (exercise/eating habits) during the study
24. have taken health oils (e.g., coconut oil/medium chain triglyceride oil) possibly rich in the ingredients assessed in the study within 3 months/are currently taking
25. take foods rich in ingredients (may affect bowel movements/research field) 4 days weekly or more
26. sometimes substitute sweets or nutritional jellies for meals

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Tsuyoshi
Middle name
Last name Takara

Organization

Medical Corporation Seishinkai, Takara Clinic

Division name

Director

Zip code

141-0022

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

TEL

03-5793-3623

Email

t-takara@takara-clinic.com


Public contact

Name of contact person

1st name Naoko
Middle name
Last name Suzuki

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan

TEL

03-3818-0610

Homepage URL


Email

nao@orthomedico.jp


Sponsor or person

Institute

ORTHOMEDICO Inc.

Institute

Department

Personal name



Funding Source

Organization

The Nisshin OilliO Group, Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Medical Corporation Seishinkai, Takara Clinic

Nerima Medical Association, Minami-machi Clinic

Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

Tel

03-5793-3623

Email

IRB@takara-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)


Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

88

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2023 Year 11 Month 15 Day

Date of IRB

2023 Year 11 Month 15 Day

Anticipated trial start date

2023 Year 12 Month 04 Day

Last follow-up date

2024 Year 04 Month 24 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 12 Month 04 Day

Last modified on

2024 Year 12 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060455